Bright Minds Biosciences Valuation

Is DRUG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DRUG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DRUG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DRUG's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DRUG?

Key metric: As DRUG is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for DRUG. This is calculated by dividing DRUG's market cap by their current book value.
What is DRUG's PB Ratio?
PB Ratio	53.5x
Book	CA$6.10m
Market Cap	CA$363.48m

DRUG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does DRUG's PB Ratio compare to its peers?

The above table shows the PB ratio for DRUG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	9x
EPRX Eupraxia Pharmaceuticals	13.5x	n/a	CA$163.9m
MDNA Medicenna Therapeutics	5.8x	60.2%	CA$126.6m
ONC Oncolytics Biotech	11.9x	37.5%	CA$114.1m
COV Covalon Technologies	4.9x	n/a	CA$109.6m
DRUG Bright Minds Biosciences	53.5x	n/a	CA$363.5m

Price-To-Book vs Peers: DRUG is expensive based on its Price-To-Book Ratio (53.5x) compared to the peer average (9x).

Price to Book Ratio vs Industry

How does DRUG's PB Ratio compare vs other companies in the CA Biotechs Industry?

2 Companies	Price / Book	Estimated Growth	Market Cap
QPT Quest PharmaTech	0.3x	n/a	US$4.23m
CURE.X Biocure Technology	0.2x	n/a	US$224.11k

No more companies available in this PB range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: DRUG is expensive based on its Price-To-Book Ratio (53.5x) compared to the Canadian Biotechs industry average (1.5x).

Price to Book Ratio vs Fair Ratio

What is DRUG's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DRUG PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	53.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate DRUG's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.50

7.6%

-44.2%

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.15

5.4%

40.5%

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.32

-12.8%

-60.6%